|
1
|
Troy JD, Atallah E, Geyer JT and Saber W:
Myelodysplastic syndromes in the United States: An update for
clinicians. Ann Med. 46:283–289. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Daver N and Cortes J: Molecular targeted
therapy in acute myeloid leukemia. Hematology. 17 (Suppl
1):S59–S62. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Stone R, Sekeres M and Garcia-Manero G:
Evolving strategies in the treatment of MDS and AML. Clin Adv
Hematol Oncol. 7:1–14. 2009.PubMed/NCBI
|
|
4
|
Buitenhuis M and Coffer PJ: The role of
the PI3K-PKB signaling module in regulation of hematopoiesis. Cell
Cycle. 8:560–566. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fruman DA and Rommel C: PI3K and cancer:
Lessons, challenges and opportunities. Nat Rev Drug Discov.
13:140–156. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Martelli AM, Evangelisti C, Chiarini F and
McCubrey JA: The phosphatidylinositol 3-kinase/Akt/mTOR signaling
network as a therapeutic target in acute myelogenous leukemia
patients. Oncotarget. 1:89–103. 2010.PubMed/NCBI
|
|
7
|
Altman JK, Sassano A and Platanias LC:
Targeting mTOR for the treatment of AML. New agents and new
directions. Oncotarget. 2:510–517. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Birkenkamp KU, Geugien M, Schepers H,
Westra J, Lemmink HH and Vellenga E: Constitutive NF-kappaB
DNA-binding activity in AML is frequently mediated by a
Ras/PI3-K/PKB-dependent pathway. Leukemia. 18:103–112. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Xu Q, Simpson SE, Scialla TJ, Bagga A and
Carroll M: Survival of acute myeloid leukemia cells requires PI3
kinase activation. Blood. 102:972–980. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Neri LM, Borgatti P, Tazzari PL, Bortul R,
Cappellini A, Tabellini G, Bellacosa A, Capitani S and Martelli AM:
The phosphoinositide 3-kinase/AKT1 pathway involvement in drug and
all-trans-retinoic acid resistance of leukemia cells. Mol
Cancer Res. 1:234–246. 2003.PubMed/NCBI
|
|
11
|
Kentsis A, Topisirovic I, Culjkovic B,
Shao L and Borden KL: Ribavirin suppresses eIF4E-mediated oncogenic
transformation by physical mimicry of the 7-methyl guanosine mRNA
cap. Proc Natl Acad Sci USA. 101:18105–18110. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Assouline S, Culjkovic B, Cocolakis E,
Rousseau C, Beslu N, Amri A, Caplan S, Leber B, Roy DC, Miller WH
Jr and Borden KL: Molecular targeting of the oncogene eIF4E in
acute myeloid leukemia (AML): A proof-of-principle clinical trial
with ribavirin. Blood. 114:257–260. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chapuis N, Tamburini J, Green AS, Vignon
C, Bardet V, Neyret A, Pannetier M, Willems L, Park S, Macone A, et
al: Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as
a new therapeutic strategy for acute myeloid leukemia. Clin Cancer
Res. 16:5424–5435. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Altman JK, Sassano A, Kaur S, Glaser H,
Kroczynska B, Redig AJ, Russo S, Barr S and Platanias LC: Dual
mTORC2/mTORC1 targeting results in potent suppressive effects on
acute myeloid leukemia (AML) progenitors. Clin Cancer Res.
17:4378–4388. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Park S, Chapuis N, Bardet V, Tamburini J,
Gallay N, Willems L, Knight ZA, Shokat KM, Azar N, Viguié F, et al:
PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase
and mTOR, has antileukemic activity in AML. Leukemia. 22:1698–1706.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zeng Z, Shi YX, Tsao T, Qiu Y, Kornblau
SM, Baggerly KA, Liu W, Jessen K, Liu Y, Kantarjian H, et al:
Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces
apoptosis in AML cells under conditions mimicking the bone marrow
microenvironment. Blood. 120:2679–2689. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Papa V, Tazzari PL, Chiarini F, Cappellini
A, Ricci F, Billi AM, Evangelisti C, Ottaviani E, Martinelli G,
Testoni N, et al: Proapoptotic activity and chemosensitizing effect
of the novel Akt inhibitor perifosine in acute myelogenous leukemia
cells. Leukemia. 22:147–160. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Huarte M: The emerging role of lncRNAs in
cancer. Nat Med. 21:1253–1261. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Iyer MK, Niknafs YS, Malik R, Singhal U,
Sahu A, Hosono Y, Barrette TR, Prensner JR, Evans JR, Zhao S, et
al: The landscape of long noncoding RNAs in the human
transcriptome. Nat Genet. 47:199–208. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Garzon R, Volinia S, Papaioannou D,
Nicolet D, Kohlschmidt J, Yan PS, Mrózek K, Bucci D, Carroll AJ,
Baer MR, et al: Expression and prognostic impact of lncRNAs in
acute myeloid leukemia. Proc Natl Acad Sci USA. 111:18679–18684.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wu S, Zheng C, Chen S, Cai X, Shi Y, Lin B
and Chen Y: Overexpression of long non-coding RNA HOTAIR predicts a
poor prognosis in patients with acute myeloid leukemia. Oncol Lett.
10:2410–2414. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mer AS, Lindberg J, Nilsson C, Klevebring
D, Wang M, Grönberg H, Lehmann S and Rantalainen M: Expression
levels of long non-coding RNAs are prognostic for AML outcome. J
Hematol Oncol. 11:522018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhu Y, Zhang X, Qi L, Cai Y, Yang P, Xuan
G and Jiang Y: HULC long noncoding RNA silencing suppresses
angiogenesis by regulating ESM-1 via the PI3K/Akt/mTOR signaling
pathway in human gliomas. Oncotarget. 7:14429–14440.
2016.PubMed/NCBI
|
|
24
|
Yao X, Yan C, Zhang L, Li Y and Wan Q:
LncRNA ENST00113 promotes proliferation, survival, and migration by
activating PI3K/Akt/mTOR signaling pathway in atherosclerosis.
Medicine. 97:e04732018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Trimarchi T, Bilal E, Ntziachristos P,
Fabbri G, Dalla-Favera R, Tsirigos A and Aifantis I: Genome-wide
mapping and characterization of Notch-regulated long noncoding RNAs
in acute leukemia. Cell. 158:593–606. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Venter JC, Adams MD, Myers EW, Li PW,
Mural RJ, Sutton GG, Smith HO, Yandell M, Evans CA, Holt RA, et al:
The sequence of the human genome. Science. 291:1304–1351. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bhan A and Mandal SS: Long noncoding RNAs:
Emerging stars in gene regulation, epigenetics and human disease.
ChemMedChem. 9:1932–1956. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wapinski O and Chang HY: Long noncoding
RNAs and human disease. Trends Cell Biol. 21:354–361. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu Z, Sun M, Lu K, Liu J, Zhang M, Wu W,
De W, Wang Z and Wang R: The long noncoding RNA HOTAIR contributes
to cisplatin resistance of human lung adenocarcinoma cells via
downregualtion of p21WAF1/CIP1 expression. PLoS One.
8:e772932013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hou Z, Xu C, Xie H, Xu H, Zhan P, Yu L and
Fang X: Long noncoding RNAs expression patterns associated with
chemo response to cisplatin based chemotherapy in lung squamous
cell carcinoma patients. PLoS One. 9:e1081332014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Naci D, El Azreq MA, Chetoui N, Lauden L,
Sigaux F, Charron D, Al-Daccak R and Aoudjit F: α2β1 integrin
promotes chemoresistance against doxorubicin in cancer cells
through extracellular signal-regulated kinase (ERK). J Biol Chem.
287:17065–17076. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lagadinou ED, Ziros PG, Tsopra OA, Dimas
K, Kokkinou D, Thanopoulou E, Karakantza M, Pantazis P,
Spyridonidis A and Zoumbos NC: c-Jun N-terminal kinase activation
failure is a new mechanism of anthracycline resistance in acute
myeloid leukemia. Leukemia. 22:1899–1908. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kweon SH, Song JH and Kim TS:
Resveratrol-mediated reversal of doxorubicin resistance in acute
myeloid leukemia cells via downregulation of MRP1 expression.
Biochem Biophys Res Commun. 395:104–110. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tao J, Lu Q, Wu D, Li P, Xu B, Qing W,
Wang M, Zhang Z and Zhang W: microRNA-21 modulates cell
proliferation and sensitivity to doxorubicin in bladder cancer
cells. Oncol Rep. 25:1721–1729. 2011.PubMed/NCBI
|
|
36
|
Fransecky L, Mochmann LH and Baldus CD:
Outlook on PI3K/AKT/mTOR inhibition in acute leukemia. Mol Cell
Ther. 3:22015. View Article : Google Scholar : PubMed/NCBI
|
